Skip Navigation
Skip to contents

Journal of Microbiology : Journal of Microbiology

OPEN ACCESS
SEARCH
Search
Advanced Search
mobile menu button

Articles

Page Path
HOME > J. Microbiol > Volume 50(4); 2012 > Article
Research Support, Non-U.S. Gov't
NOTE] Biological and Genetic Properties of SA14-14-2, a Live-Attenuated Japanese Encephalitis Vaccine That Is Currently Available for Humans
Byung-Hak Song 1, Gil-Nam Yun 1, Jin-Kyoung Kim 1, Sang-Im Yun 1,2, Young-Min Lee 1,2
Journal of Microbiology 2012;50(4):698-706.
DOI: https://doi.org/10.1007/s12275-012-2336-6
Published online: August 25, 2012
1Department of Microbiology, College of Medicine, Chungbuk National University, Cheongju 361-763, Republic of Korea, 2Department of Animal, Dairy and Veterinary Sciences, Utah Science Technology and Research (USTAR), College of Agriculture, Utah State University, Logan, UT 84322-4815, United States of America
Corresponding author:  Young-Min Lee , Tel: +1-435-797-9667, 
Received: 2 July 2012   • Accepted: 13 July 2012
prev next
  • 81 Views
  • 0 Download
  • 14 Crossref
  • 28 Scopus
Full Article

Abstract

Japanese encephalitis virus (JEV), a mosquito-borne flavivirus, is a major cause of acute encephalitis, a disease of significance for global public health. In the absence of antiviral therapy to treat JEV infection, vaccination is the most effective method of preventing the disease. In JE-endemic areas, the most widely used vaccine to date is SA14-14-2, a live-attenuated virus derived from its virulent parent SA14. In this study, we describe the biological properties of SA14-14-2, both in vitro and in vivo, and report the genetic characteristics of its genomic RNA. In BHK-21 (hamster kidney) cells, SA14-14-2 displayed a slight delay in plaque formation and growth kinetics when compared to a virulent JEV strain, CNU/LP2, with no decrease in maximum virus production. The delay in viral growth was also observed in two other cell lines, SH-SY5Y (human neuroblastoma) and C6/36 (mosquito larva), which are potentially relevant to JEV pathogenesis and transmission. In 3-week-old ICR mice, SA14-14-2 did not cause any symptoms or death after either intracerebral or peripheral inoculation with a maximum dose of up to 1.5×103 plaqueforming units (PFU) per mouse. The SA14-14-2 genome consisted of 10977 nucleotides, one nucleotide longer than all the previously reported genomes of SA14-14-2, SA14 and two other SA14-derived attenuated viruses. This difference was due to an insertion of one G nucleotide at position 10701 in the 3' noncoding region. Also, we noted a significant number of nucleotide and/or amino acid substitutions throughout the genome of SA14-14-2, except for the prM protein-coding region, that differed from SA14 and/or the other two attenuated viruses. Our results, together with others’, provide a foundation not only for the study of JEV virulence but also for the development of new and improved vaccines for JEV.

  • Cite this Article
    Cite this Article
    export Copy Download
    Close
    Download Citation
    Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.
    Format:
    • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
    • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
    Include:
    • Citation for the content below
    NOTE] Biological and Genetic Properties of SA14-14-2, a Live-Attenuated Japanese Encephalitis Vaccine That Is Currently Available for Humans
    J. Microbiol. 2012;50(4):698-706.   Published online August 25, 2012
    DOI: https://doi.org/10.1007/s12275-012-2336-6
    Close
Related articles
Journal of Microbiology : Journal of Microbiology
© The Microbiological Society of Korea.
TOP